As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
Will Tariffs Hit Pharmaceuticals? The Calm Before the Storm While the pharmaceutical industry may have narrowly escaped the latest wave of U.S. ta...
Croda is pleased to announce the appointments of Stephen Oxley as Chief Financial Officer (CFO) and Executive Director, and Dr. Thomas Riermeier as Presi...
WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with ...
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Rama...
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, de...
Appointment of three internal senior executives ensures strategic continuity with a new era of leadership Jean-Charles Wirth to become CEO Life Scienc...
Artificial intelligence is reshaping oncology, and ImpriMed is at the forefront of this transformation. With its AI-powered Personalized Prediction Profi...
AstraZeneca delivered $54.1 billion in total revenue for FY 2024, a 21% increase at constant exchange rates (CER), fueled by strong growth across oncolog...
Illumina, led by CEO Jacob Thaysen, delivered a Q4 revenue of $1.1 billion, reflecting a steady 1% year-over-year increase, w...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its financial results for the first quarter ...
Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth W...
Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...
© 2025 Biopharma Boardroom. All Rights Reserved.